![conference banner](/images/conference-banner.jpeg)
Abstract
Cervical cancer is the second most common malignancy among women worldwide. The prime causal factor of the disease is a persistent infection with human papillomavirus (HPV) with individuals failing to mount a sufficient immune response against the virus. Despite the current success of HPV16- and 18-specific prophylactic vaccination, established HPV infections and associated neoplasia require therapeutic vaccines with the induction of cellular immunity. The sustained expression of early proteins E6 and E7 from major oncogenic HPV genotypes in cervical lesions are ideal targets for the design of immunotherapeutic strategies. These strategies, particularly subunit vaccines, may require additional help from immunomodulators to enhance HPV-specific cellular responses. This review discusses recent studies, published since 2008, relating to immunotherapeutic strategies against HPV that include immunomodulators. These immunomodulators fall within the category of toll-like receptor adjuvants for innate immune activation, adjuvants directly contributing to adaptive immunity, such as cytokines and costimulatory molecules, and those that target tumor-induced immunosuppressive mechanisms. Using a combination of these strategies with delivery-based approaches may be most beneficial for the success of therapeutic vaccines against HPV-induced neoplasia in the clinic.
Keywords: Adjuvant, cervical cancer, HPV, human papillomavirus, immunomodulators, immunotherapy, vaccine.
Anti-Cancer Agents in Medicinal Chemistry
Title:HPV-Specific Immunotherapy: Key Role for Immunomodulators
Volume: 14 Issue: 2
Author(s): Stephanie Van de Wall, Hans W Nijman and Toos Daemen
Affiliation:
Keywords: Adjuvant, cervical cancer, HPV, human papillomavirus, immunomodulators, immunotherapy, vaccine.
Abstract: Cervical cancer is the second most common malignancy among women worldwide. The prime causal factor of the disease is a persistent infection with human papillomavirus (HPV) with individuals failing to mount a sufficient immune response against the virus. Despite the current success of HPV16- and 18-specific prophylactic vaccination, established HPV infections and associated neoplasia require therapeutic vaccines with the induction of cellular immunity. The sustained expression of early proteins E6 and E7 from major oncogenic HPV genotypes in cervical lesions are ideal targets for the design of immunotherapeutic strategies. These strategies, particularly subunit vaccines, may require additional help from immunomodulators to enhance HPV-specific cellular responses. This review discusses recent studies, published since 2008, relating to immunotherapeutic strategies against HPV that include immunomodulators. These immunomodulators fall within the category of toll-like receptor adjuvants for innate immune activation, adjuvants directly contributing to adaptive immunity, such as cytokines and costimulatory molecules, and those that target tumor-induced immunosuppressive mechanisms. Using a combination of these strategies with delivery-based approaches may be most beneficial for the success of therapeutic vaccines against HPV-induced neoplasia in the clinic.
Export Options
About this article
Cite this article as:
Wall Van de Stephanie, Nijman W Hans and Daemen Toos, HPV-Specific Immunotherapy: Key Role for Immunomodulators, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (2) . https://dx.doi.org/10.2174/187152061402140128163306
DOI https://dx.doi.org/10.2174/187152061402140128163306 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer
Current Topics in Medicinal Chemistry Recent Advances in Designing Substrate-Competitive Protein Kinase Inhibitors
Current Pharmaceutical Design Using Cytokines to Treat Cervical Intraepithelial and Invasive Neoplasia
Recent Patents on Anti-Cancer Drug Discovery Recent Updates on the Management of Human Papillomavirus-related Cancers
Current Cancer Therapy Reviews Cancer Proteomics: New Horizons and Insights into Therapeutic Applications
Current Proteomics Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives
Current Pharmaceutical Biotechnology PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Targeting the Mannose Receptor with Mannosylated Subunit Vaccines
Current Medicinal Chemistry Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Clonetics
Current Drug Metabolism Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Peptide-Drug Conjugate: A Novel Drug Design Approach
Current Medicinal Chemistry Naphthoquinone Derivatives Isolated from Plants: Recent Advances in Biological Activity
Mini-Reviews in Medicinal Chemistry Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry A Review Exploring Therapeutic Worth of 1,3,4-Oxadiazole Tailored Compounds
Mini-Reviews in Medicinal Chemistry Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology The Human Trypanolytic Factor: A Drug Shaped Naturally
Infectious Disorders - Drug Targets Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology